- Galmed Pharmaceuticals (GLMD, Financial) identifies a proprietary 70-protein biomarker signature for Aramchol.
- This discovery opens potential multi-billion-dollar markets beyond liver diseases.
- Strategic collaboration with Proteas Health enhances precision in cardiometabolic therapeutic development.
Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, has identified a groundbreaking proprietary pharmacodynamic biomarker signature for its lead candidate, Aramchol. This discovery, derived from Phase 3 ARMOR study data, showcases Aramchol's potential beyond its initial liver disease applications. The significant findings highlight Aramchol’s therapeutic possibilities in cardiometabolic and inflammatory conditions.
The newly identified 70-protein signature exhibited notable reductions in systemic inflammation, cardiac stress, and atherosclerotic drivers. Among the critical outcomes is a decrease in Atrial Natriuretic Peptide (ANP), a marker for heart failure, and upregulation of the enzyme KDM4C, which is associated with liver fibrosis suppression. These transformative insights were achieved in collaboration with Proteas Health, leveraging advanced proteomics and AI technologies.
This pivotal development positions Galmed to extend Aramchol's application into expansive multi-billion-dollar markets beyond MASH/NASH, particularly into heart failure and broader cardiometabolic conditions. Furthermore, the biomarker signature may serve as a unique companion diagnostic tool, enhancing clinical decision-making and providing a pathway for strategic partnerships, licensing, or merger and acquisition engagements.
Allen Baharaff, President and CEO of Galmed, emphasized the broader implications of the dataset, stating, "This dataset validates our long-standing belief that Aramchol is more than a liver drug — it’s potentially a systemically active therapeutic with broad applicability across high-value indications.”
The collaboration with Proteas Health situates Galmed at the forefront of AI-driven biomarker-guided therapeutic development, promising new commercial and clinical pathways as they navigate future regulatory discussions and trials.
